These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 28945897

  • 1. Body Composition and Ectopic Lipid Changes With Biochemical Control of Acromegaly.
    Bredella MA, Schorr M, Dichtel LE, Gerweck AV, Young BJ, Woodmansee WW, Swearingen B, Miller KK.
    J Clin Endocrinol Metab; 2017 Nov 01; 102(11):4218-4225. PubMed ID: 28945897
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Increased GH/IGF-I Axis Activity Relates to Lower Hepatic Lipids and Phosphor Metabolism.
    Fellinger P, Beiglböck H, Semmler G, Pfleger L, Smajis S, Baumgartner C, Gajdosik M, Marculescu R, Vila G, Winhofer Y, Scherer T, Trauner M, Kautzky-Willer A, Krssak M, Krebs M, Wolf P.
    J Clin Endocrinol Metab; 2023 Sep 18; 108(10):e989-e997. PubMed ID: 37104943
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Associations between body composition, circulating interleukin-1 receptor antagonist, osteocalcin, and insulin metabolism in active acromegaly.
    Ueland T, Fougner SL, Godang K, Lekva T, Schurgers LJ, Scholz H, Halvorsen B, Schreiner T, Aukrust P, Bollerslev J.
    J Clin Endocrinol Metab; 2010 Jan 18; 95(1):361-8. PubMed ID: 19880791
    [Abstract] [Full Text] [Related]

  • 6. Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly.
    Lin E, Wexler TL, Nachtigall L, Tritos N, Swearingen B, Hemphill L, Loeffler J, Biller BM, Klibanski A, Miller KK.
    Clin Endocrinol (Oxf); 2012 Sep 18; 77(3):430-8. PubMed ID: 22315983
    [Abstract] [Full Text] [Related]

  • 7. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment.
    Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D'Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V, Tamburrano G.
    Clin Endocrinol (Oxf); 2003 Oct 18; 59(4):492-9. PubMed ID: 14510913
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The Metabolic Risk in Patients Newly Diagnosed with Acromegaly Is Related to Fat Distribution and Circulating Adipokines and Improves after Treatment.
    Olarescu NC, Heck A, Godang K, Ueland T, Bollerslev J.
    Neuroendocrinology; 2016 Oct 18; 103(3-4):197-206. PubMed ID: 25592241
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. COMPARISON OF CABERGOLINE VERSUS RALOXIFENE ADD-ON THERAPY TO LONG-ACTING SOMATOSTATIN ANALOGUE IN PATIENTS WITH INADEQUATELY CONTROLLED ACROMEGALY: A RANDOMIZED OPEN LABEL CLINICAL TRIAL.
    Imani M, Khamseh ME, Asadi P, Ghorbani M, Akbari H, Alaei-Shahmiri F, Honardoost M, Kaynama MR, Malek M.
    Endocr Pract; 2018 Jun 18; 24(6):542-547. PubMed ID: 29949429
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation.
    Lo JC, Mulligan K, Noor MA, Schwarz JM, Halvorsen RA, Grunfeld C, Schambelan M.
    J Clin Endocrinol Metab; 2001 Aug 18; 86(8):3480-7. PubMed ID: 11502767
    [Abstract] [Full Text] [Related]

  • 15. [Abnormalities of carbohydrate metabolism in acromegaly].
    Biagetti B, Obiols G, Valladares S, Arnez L, Dalama B, Mesa J.
    Med Clin (Barc); 2013 Nov 16; 141(10):442-6. PubMed ID: 24012444
    [Abstract] [Full Text] [Related]

  • 16. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
    Cozzi R, Attanasio R, Lodrini S, Lasio G.
    Clin Endocrinol (Oxf); 2004 Aug 16; 61(2):209-15. PubMed ID: 15272916
    [Abstract] [Full Text] [Related]

  • 17. Inflammatory adipokines contribute to insulin resistance in active acromegaly and respond differently to different treatment modalities.
    Olarescu NC, Ueland T, Godang K, Lindberg-Larsen R, Jørgensen JO, Bollerslev J.
    Eur J Endocrinol; 2014 Jan 16; 170(1):39-48. PubMed ID: 24092547
    [Abstract] [Full Text] [Related]

  • 18. Biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (SA) treated patients.
    Christiansen Arlien-Søborg M, Trolle C, Alvarson E, Bæk A, Dal J, Otto Lunde Jørgensen J.
    Endocrine; 2017 Jun 16; 56(3):589-594. PubMed ID: 28260207
    [Abstract] [Full Text] [Related]

  • 19. Ectopic lipid deposition and insulin resistance in patients with GH disorders before and after treatment.
    Arlien-Søborg MC, Madsen MA, Dal J, Krusenstjerna-Hafstrøm T, Ringgaard S, Skou N, Høgild M, Jørgensen JOL.
    Eur J Endocrinol; 2023 Jan 10; 188(1):. PubMed ID: 36651164
    [Abstract] [Full Text] [Related]

  • 20. Long-term Outcome of Body Composition, Ectopic Lipid, and Insulin Resistance Changes With Surgical Treatment of Acromegaly.
    Kuker AP, Shen W, Jin Z, Chen J, Bruce JN, Freda PU.
    J Endocr Soc; 2023 Mar 06; 7(5):bvad028. PubMed ID: 36922916
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.